Mission Bay Capital, a San Francisco, CA-based early-stage life-science venture capital firm investing in innovative entrepreneurs working on vital medical and environmental challenges, closed its third fund, at $60M.
Investors include Astellas Venture Management (a corporate venture capital of Astellas Pharma Inc.), Banyan Pacific Capital, Eli Lilly and Company, Mayfield, UC Investments, Wilson Sonsini Goodrich & Rosati, and Zambon (through Zcube, research venture of the group) as well as long-time limited partners and family offices.
With Fund III, the firm will continue to invest broadly in biotechnology innovations brought to them by MBC BioLabs incubator entrepreneurs and surrounding universities. It invests in companies seeking to diagnose and provide treatments for unmet medical needs, to deliver natural solutions to the materials we consume, and to produce sustainable, healthy foods.
Led by Douglas Crawford, Managing Director, Mission Bay Capital leverages MBC BioLabs, the Bay Area’s premier life-science incubator, which helps early-stage biotech companies with state-of-the-art equipment, a community and a la carte business services, to enable entrepreneurial scientists to perform their research fast and focused.
Since opening in 2013, MBC BioLabs has helped launch 138 companies which have gone on to raise over $3.5 billion.
We’re excited about this next chapter in our firm and in the field of biotechnology.
FinSMEs
16/09/2019